Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1905 in severe uncontrolled asthma
NCT07098403Phase 3Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1905 in asthma, sponsored by Hengrui Therapeutics. Started Sep 2025; status: recruiting.
02
Drugs
SHR-1905
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07098403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07098403.